Table of Content


1 INTRODUCTION (Page No. - 32)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 NEUROMODULATION MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH DATA
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                    TABLE 1 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                    FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
                    FIGURE 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
                    FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS
    2.6 RISK ASSESSMENT
          TABLE 2 RISK ASSESSMENT: NEUROMODULATION MARKET
    2.7 LIMITATIONS
           2.7.1 METHODOLOGY-RELATED LIMITATIONS
           2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 7 NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 8 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 NEUROMODULATION MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 50)
    4.1 NEUROMODULATION MARKET OVERVIEW
          FIGURE 11 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE GROWTH IN NEUROMODULATION MARKET
    4.2 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE & COUNTRY (2021)
          FIGURE 12 INTERNAL NEUROMODULATION ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
    4.3 GEOGRAPHIC GROWTH OPPORTUNITIES IN NEUROMODULATION MARKET
          FIGURE 13 COUNTRIES IN ASIA PACIFIC TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 14 NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising prevalence of neurological disorders and nerve injuries
                    5.2.1.2 Growing focus on neuromodulation & neurostimulation technologies
                    5.2.1.3 Expanding applications of neuromodulation
                                TABLE 3 INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS
                                FIGURE 15 RESEARCH PAPERS PUBLISHED (2011–2021)
                    5.2.1.4 Growing geriatric population and subsequent increase in prevalence of neurological disorders
                    5.2.1.5 Government support for research on neurological disorders
                                FIGURE 16 FUNDING FOR RESEARCH BY NIH (US)
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of neuromodulation procedures
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging economies
                                FIGURE 17 GROWTH IN CURRENT PER CAPITA HEALTHCARE EXPENDITURE, 2012–2019
           5.2.4 CHALLENGES
                    5.2.4.1 Stringent regulatory frameworks and time-consuming approval processes
                    5.2.4.2 Preference for drug therapies over neuromodulation products
                    5.2.4.3 Shortage of trained professionals
                    5.2.4.4 Product recalls
                                TABLE 4 MAJOR PRODUCT RECALLS
    5.3 SCENARIO-BASED MARKET ASSESSMENT
           5.3.1 NEUROMODULATION MARKET
                    FIGURE 18 PESSIMISTIC SCENARIO
                    FIGURE 19 OPTIMISTIC SCENARIO
                    FIGURE 20 REALISTIC SCENARIO
    5.4 VALUE CHAIN ANALYSIS
          FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
           5.4.1 RESEARCH & DEVELOPMENT
           5.4.2 MANUFACTURING & ASSEMBLY
           5.4.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
    5.5 SUPPLY CHAIN ANALYSIS
          FIGURE 22 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.6 TECHNOLOGY ANALYSIS
    5.7 PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT FROM NEW ENTRANTS
           5.7.2 INTENSITY OF COMPETITIVE RIVALRY
           5.7.3 BARGAINING POWER OF BUYERS
           5.7.4 BARGAINING POWER OF SUPPLIERS
           5.7.5 THREAT FROM SUBSTITUTES
    5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
           5.8.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
                    FIGURE 23 INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS, BY TECHNOLOGY
                    TABLE 5 INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS FOR THE TOP 3 TECHNOLOGIES (%)
           5.8.2 BUYING CRITERIA
                    FIGURE 24 KEY BUYING CRITERIA FOR TOP 2 END USERS
                    TABLE 6 KEY BUYING CRITERIA, BY END USER
    5.9 REGULATORY LANDSCAPE
          TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION
           5.9.1 BY REGION
                    5.9.1.1 North America
                    5.9.1.2 Europe
                    5.9.1.3 Asia Pacific
                               5.9.1.3.1 India
                               5.9.1.3.2 China
    5.10 PATENT ANALYSIS
    5.11 KEY CONFERENCES AND EVENTS IN 2022
           TABLE 8 LIST OF CONFERENCES & EVENTS
    5.12 PRICING ANALYSIS
           TABLE 9 PRICE RANGE FOR NEUROMODULATION DEVICES AND PROCEDURES
    5.13 TRADE ANALYSIS
           TABLE 10 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)
           TABLE 11 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)
    5.14 ECOSYSTEM ANALYSIS
           5.14.1 ROLE IN ECOSYSTEM
           5.14.2 KEY PLAYERS IN THE NEUROMODULATION MARKET
    5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

6 NEUROMODULATION MARKET, BY TYPE (Page No. - 75)
    6.1 INTRODUCTION
          TABLE 12 NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
    6.2 INTERNAL NEUROMODULATION
          TABLE 13 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 14 INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 15 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 16 EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 17 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 18 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.2.1 SPINAL CORD STIMULATION
                    6.2.1.1 Growing incidence of spinal cord injuries to support market growth
                                TABLE 19 SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 20 SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
                                TABLE 21 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 22 EUROPE: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 23 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 24 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.2.2 DEEP BRAIN STIMULATION
                    6.2.2.1 DBS allows stimulation parameters to be changed to reduce side effects
                                TABLE 25 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 26 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
                                TABLE 27 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 28 EUROPE: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 29 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 30 REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.2.3 VAGUS NERVE STIMULATION
                    6.2.3.1 Non-invasive vagus nerve stimulation does not require surgical implantation—a key benefit
                                TABLE 31 VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 32 VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
                                TABLE 33 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 34 EUROPE: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 35 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 36 REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.2.4 SACRAL NERVE STIMULATION
                    6.2.4.1 Widening scope of sacral nerve stimulation to drive growth
                                TABLE 37 SACRAL NERVE STIMULATION DEVICES OFFERED
                                TABLE 38 SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 39 SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
                                TABLE 40 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 41 EUROPE: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 42 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 43 REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.2.5 GASTRIC ELECTRICAL STIMULATION
                    6.2.5.1 Growing number of people suffering from severe GERD and gastroparesis to fuel market growth
                                TABLE 44 GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 45 GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
                                TABLE 46 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 47 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 48 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 49 REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.3 EXTERNAL NEUROMODULATION
          TABLE 50 EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 51 EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 52 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 53 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 54 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 55 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION
                    6.3.1.1 Extensive use in healthcare, low cost, and ease of use to favor market growth
                                TABLE 56 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 57 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
                                TABLE 58 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 59 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 60 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 61 REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.3.2 TRANSCRANIAL MAGNETIC STIMULATION
                    6.3.2.1 Minimal patient discomfort associated with TMS supports demand
                                TABLE 62 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 63 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
                                TABLE 64 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 65 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 66 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 67 REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.3.3 RESPIRATORY ELECTRICAL STIMULATION
                    6.3.3.1 High treatment efficacy to fuel market growth
                                TABLE 68 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 69 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)
                                TABLE 70 NORTH AMERICA: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 71 EUROPE: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 72 ASIA PACIFIC: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 73 REST OF THE WORLD: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)

7 NEUROMODULATION MARKET, BY APPLICATION (Page No. - 102)
    7.1 INTRODUCTION
    7.2 SPINAL CORD STIMULATION MARKET, BY APPLICATION
          TABLE 74 SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           7.2.1 CHRONIC PAIN
                    7.2.1.1 High incidence of chronic pain supports market growth
                                TABLE 75 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2020–2027 (USD MILLION)
           7.2.2 FAILED BACK SURGERY SYNDROME
                    7.2.2.1 Growing incidence of FBSS due to rising number of surgeries each year to drive demand for stimulation technologies
                                TABLE 76 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2020–2027 (USD MILLION)
           7.2.3 ISCHEMIA
                    7.2.3.1 High effectiveness of neuromodulation for ischemia treatment to support market growth
                                TABLE 77 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2020–2027 (USD MILLION)
    7.3 DEEP BRAIN STIMULATION MARKET, BY APPLICATION
          TABLE 78 DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           7.3.1 PARKINSON’S DISEASE
                    7.3.1.1 Rising incidence of Parkinson’s disease and growing R&D activity in this area to drive growth
                                TABLE 79 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION)
           7.3.2 TREMORS
                    7.3.2.1 High efficacy of DBS in treating tremors boosts demand
                                TABLE 80 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2020–2027 (USD MILLION)
           7.3.3 DEPRESSION
                    7.3.3.1 Lack of evidence of efficacy of DBS for depression treatment to limit market growth
                                TABLE 81 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION)
           7.3.4 OTHER DBS APPLICATIONS
                    TABLE 82 DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
    7.4 SACRAL NERVE STIMULATION MARKET, BY APPLICATION
          TABLE 83 SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           7.4.1 URINE INCONTINENCE
                    7.4.1.1 High incidence of urine incontinence offers growth opportunities
                                TABLE 84 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2020–2027 (USD MILLION)
           7.4.2 FECAL INCONTINENCE
                    7.4.2.1 Reduced symptom recurrence supports use of SNS in fecal incontinence treatment
                                TABLE 85 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2020–2027 (USD MILLION)
    7.5 VAGUS NERVE STIMULATION MARKET, BY APPLICATION
          TABLE 86 VAGUS NERVE MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           7.5.1 EPILEPSY
                    7.5.1.1 Advantages associated with VNS in epilepsy treatment to propel market
                                TABLE 87 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2020–2027 (USD MILLION)
           7.5.2 OTHER VNS APPLICATIONS
                    TABLE 88 VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
    7.6 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION
          TABLE 89 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           7.6.1 GASTROPARESIS
                    7.6.1.1 GES treatment reduces hospitalizations for patients affected by gastroparesis
                                TABLE 90 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2020–2027 (USD MILLION)
           7.6.2 OBESITY
                    7.6.2.1 Risks associated with gastric bypass to increase preference for GES
                                TABLE 91 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2020–2027 (USD MILLION)
    7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION
          TABLE 92 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           7.7.1 TREATMENT-RESISTANT DEPRESSION
                    7.7.1.1 TENS induces relaxed state in patients suffering from treatment-resistant depression
                                TABLE 93 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2020–2027 (USD MILLION)
           7.7.2 OTHER TENS APPLICATIONS
                                TABLE 94 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
    7.8 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION
          TABLE 95 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           7.8.1 DEPRESSION
                    7.8.1.1 Increased acceptance among patients to drive demand for TMS
                                TABLE 96 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION)
           7.8.2 MIGRAINE
                    7.8.2.1 High prevalence of migraine to support market growth
                                TABLE 97 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2020–2027 (USD MILLION)
    7.9 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY APPLICATION
           7.9.1 SPINAL CORD INJURY
                    7.9.1.1 Rising incidence of spinal cord injuries ensures sustained demand for RES
                                TABLE 98 RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2020–2027 (USD MILLION)

8 NEUROMODULATION MARKET, BY REGION (Page No. - 117)
    8.1 INTRODUCTION
           TABLE 99 NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
    8.2 NORTH AMERICA
           FIGURE 25 NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT
           TABLE 100 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 101 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 102 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 103 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 104 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 105 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 106 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 107 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 108 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 109 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 110 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           8.2.1 US
                    8.2.1.1 Large number of prominent players makes US the largest market
                                TABLE 111 US: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 112 US: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 113 US: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.2.2 CANADA
                    8.2.2.1 Rising healthcare expenditure and increasing disease prevalence will drive demand for neurostimulation
                                TABLE 114 NEUROLOGICAL CONDITIONS PREVALENT IN CANADA
                                TABLE 115 CANADA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 116 CANADA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 117 CANADA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
    8.3 EUROPE
          TABLE 118 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 119 EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 120 EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 121 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 122 EUROPE: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 123 EUROPE: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 124 EUROPE: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 125 EUROPE: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)           TABLE 126 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 127 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 128 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           8.3.1 GERMANY
                    8.3.1.1 Favorable government initiatives ensure strong market growth in Germany
                                TABLE 129 GERMANY: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 130 GERMANY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 131 GERMANY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.3.2 UK
                    8.3.2.1 High public- and private-sector investments fuel market growth
                                TABLE 132 UK: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 133 UK: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 134 UK: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.3.3 FRANCE
                    8.3.3.1 Availability of insurance and favorable healthcare reforms contribute to growth
                                TABLE 135 FRANCE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 136 FRANCE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 137 FRANCE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.3.4 ITALY
                    8.3.4.1 Easy access to healthcare services makes Italy a lucrative market
                                TABLE 138 ITALY: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 139 ITALY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 140 ITALY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.3.5 SPAIN
                    8.3.5.1 Growing government initiatives may support market growth in Spain
                                TABLE 141 SPAIN: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 142 SPAIN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 143 SPAIN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.3.6 REST OF EUROPE
                    TABLE 144 PERCENTAGE OF POPULATION AGED 65 YEARS OR OVER, 2019 VS. 2050
                    TABLE 145 REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 146 REST OF EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 147 REST OF EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
    8.4 ASIA PACIFIC
           FIGURE 26 ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT
           TABLE 148 ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 149 ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 150 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 151 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 152 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 153 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 154 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 155 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 156 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 157 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 158 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           8.4.1 JAPAN
                    8.4.1.1 Japan dominates the APAC market for neuromodulation
                                TABLE 159 JAPAN: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 160 JAPAN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 161 JAPAN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.4.2 CHINA
                    8.4.2.1 Growing geriatric population will favor market growth in China
                                TABLE 162 CHINA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 163 CHINA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 164 CHINA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.4.3 INDIA
                    8.4.3.1 Improvements in healthcare infrastructure in the country will support market
                                TABLE 165 INDIA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 166 INDIA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 167 INDIA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.4.4 REST OF ASIA PACIFIC
                    TABLE 168 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 169 REST OF ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 170 REST OF ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
    8.5 REST OF THE WORLD
           TABLE 171 REST OF THE WORLD: NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)
           TABLE 172 REST OF THE WORLD: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 173 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 174 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 175 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 176 REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 177 REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 178 REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 179 REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 180 REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 181 REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           8.5.1 LATIN AMERICA
                    8.5.1.1 Latin America holds largest share of neuromodulation market in RoW
                                TABLE 182 LATIN AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 183 LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 184 LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.5.2 MIDDLE EAST & AFRICA
                    8.5.2.1 High cost of neuromodulation to hamper market growth
                                TABLE 185 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 186 MIDDLE EAST & AFRICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 187 MIDDLE EAST & AFRICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE (Page No. - 158)
    9.1 OVERVIEW
    9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
           TABLE 188 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
    9.3 REVENUE SHARE ANALYSIS
          FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET
    9.4 MARKET SHARE ANALYSIS
           TABLE 189 NEUROMODULATION MARKET: DEGREE OF COMPETITION
    9.5 COMPANY EVALUATION MATRIX
           9.5.1 STARS
           9.5.2 EMERGING LEADERS
           9.5.3 PERVASIVE PLAYERS
           9.5.4 PARTICIPANTS
                    FIGURE 28 COMPANY EVALUATION MATRIX: NEUROMODULATION MARKET
    9.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS
           9.6.1 PROGRESSIVE COMPANIES
           9.6.2 STARTING BLOCKS
           9.6.3 RESPONSIVE COMPANIES
           9.6.4 DYNAMIC COMPANIES
                    FIGURE 29 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: NEUROMODULATION MARKET
    9.7 COMPANY FOOTPRINT ANALYSIS
           TABLE 190 OVERALL FOOTPRINT OF COMPANIES
           TABLE 191 REGIONAL FOOTPRINT OF COMPANIES
           TABLE 192 TYPE FOOTPRINT OF COMPANIES
    9.8 COMPETITIVE BENCHMARKING
           TABLE 193 NEUROMODULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES
    9.9 COMPETITIVE SCENARIO
           9.9.1 PRODUCT LAUNCHES & APPROVALS
                    TABLE 194 KEY PRODUCT LAUNCHES & APPROVALS
           9.9.2 DEALS
                    TABLE 195 KEY DEALS
           9.9.3 OTHER DEVELOPMENTS
                    TABLE 196 OTHER KEY DEVELOPMENTS

10 COMPANY PROFILES (Page No. - 170)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     10.1 KEY PLAYERS
             10.1.1 MEDTRONIC PLC
                        TABLE 197 MEDTRONIC PLC: BUSINESS OVERVIEW
                        FIGURE 30 MEDTRONIC PLC: COMPANY SNAPSHOT (2021)
             10.1.2 BOSTON SCIENTIFIC CORPORATION
                        TABLE 198 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
                        FIGURE 31 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2021)
             10.1.3 ABBOTT LABORATORIES
                        TABLE 199 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             10.1.4 LIVANOVA PLC
                        TABLE 200 LIVANOVA PLC: BUSINESS OVERVIEW
                        FIGURE 33 LIVANOVA PLC: COMPANY SNAPSHOT (2021)
             10.1.5 NEVRO CORPORATION
                        TABLE 201 NEVRO CORPORATION: BUSINESS OVERVIEW
                        FIGURE 34 NEVRO CORPORATION: COMPANY SNAPSHOT (2021)
             10.1.6 NEUROSIGMA, INC.
                        TABLE 202 NEUROSIGMA, INC.: BUSINESS OVERVIEW
             10.1.7 NEUROPACE, INC.
                        TABLE 203 NEUROPACE, INC.: BUSINESS OVERVIEW
                        FIGURE 35 NEUROPACE, INC.: COMPANY SNAPSHOT (2021)
             10.1.8 SOTERIX MEDICAL INC.
                        TABLE 204 SOTERIX MEDICAL INC.: BUSINESS OVERVIEW
             10.1.9 SYNAPSE BIOMEDICAL INC.
                        TABLE 205 SYNAPSE BIOMEDICAL INC.: BUSINESS OVERVIEW
             10.1.10 ALEVA NEUROTHERAPEUTICS SA
                        TABLE 206 ALEVA NEUROTHERAPEUTICS SA: BUSINESS OVERVIEW
             10.1.11 THERANICA BIO-ELECTRONICS LTD.
                        TABLE 207 THERANICA BIO-ELECTRONICS LTD.: BUSINESS OVERVIEW
             10.1.12 NEURONETICS
                        TABLE 208 NEURONETICS: BUSINESS OVERVIEW
                        FIGURE 36 NEURONETICS: COMPANY SNAPSHOT (2021)
             10.1.13 BIONESS
                        TABLE 209 BIONESS: BUSINESS OVERVIEW
             10.1.14 BIOINDUCTION
                        TABLE 210 BIOINDUCTION: BUSINESS OVERVIEW
     10.2 OTHER PLAYERS
             10.2.1 GIMER MEDICAL
             10.2.2 GTX MEDICAL
             10.2.3 HELIUS MEDICAL TECHNOLOGIES
             10.2.4 MICROTRANSPONDER
             10.2.5 BLUEWIND MEDICAL
             10.2.6 ELECTROCORE, INC.
             10.2.7 RENISHAW PLC
             10.2.8 TVNS TECHNOLOGIES GMBH
             10.2.9 BIOWAVEGO USA
             10.2.10 CARDIONOMIC, INC.
             10.2.11 SALUDA MEDICAL PTY LTD.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX (Page No. - 207)
     11.1 DISCUSSION GUIDE
     11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     11.3 AVAILABLE CUSTOMIZATIONS
     11.4 RELATED REPORTS
     11.5 AUTHOR DETAILS